Provided herein is a large immuno-sorbent surface area assay (ALISSA) for the rapid and sensitive detection of botulinum neurotoxins (BoNTs) and anthrax toxin. This assay is designed to capture a low number of toxin molecules and to measure their intrinsic protease activity via conversion of a fluorogenic or luminescent substrate. Also provided herein are novel peptides that can be specifically cleaved by BoNT and novel peptides that are resistant to cleavage by BoNT. The combination of these cleavable and control peptides can be used for implementation of an exemplary ALISSA used to specifically detect BoNT enzymatic activity. Furthermore, the ALISSA as described herein may also be used in a column based format for use in a high-throughput system for testing large quantities of samples.

The present invention generally relates to methods of generating antibodies against a species of pathogen that involve identifying the pathogen that is most genetically representative of member of pathogen species and using the identified pathogen to generate an antibody.

The present invention generally relates to methods of generating antibodies against a species of pathogen that involve identifying the pathogen that is most genetically representative of member of pathogen species and using the identified pathogen to generate an antibody.

The present invention relates to antibody molecules that bind to Wall Teichoic Acid (WTA) or Capsular Polysaccharides (CP) such as Capsular Polysaccharides type 5 (CP5). The invention relates in particular to antibody molecules of the IgG isotype having a mutation in the Fc domain that enhances clustering of IgG molecules after target binding. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of infectious diseases using these compositions

A hybridoma cell line of secreting cyproheptadine monoclonal antibodies with a preservation number of CGMCC No. 14699 belongs to the field of food safety immunological detection. BALB/c mice are immunized through one time immunization with complete freund's adjuvant, three times of booster immunization with incomplete freund's adjuvant and one time of rush immunization with cyproheptadine complete antigen without adjuvant; the spleen cells from BALB/C mice immunized with high potency and low value of IC50 are fused with murine myeloma cells; and then the hybridoma cell line is obtained through indirect competitive ELISA screening and three sub-clones. The monoclonal antibody secreted by this cell line has good specificity and detection sensitivity to cyproheptadine (value of IC50 is 0.37 ng/ml), being suitable for detection of cyproheptadine in food.

The invention relates to methods for generating an aerosol by nebulization of a composition comprising polyclonal immunoglobulin (Ig). The selection of an efficient membrane nebulizer and a composition optimized for nebulization with such membrane nebulizer results in a particularly efficient method of generating an aerosol for administration of Ig to the respiratory tract.

Disclosed are B5 hybridoma and a B5 monoclonal antibody to Burkholderia mallei, Burkholderia pseudomallei, or Burkholderia thailandensis and methods of use. Also disclosed are isolated binding fragments, isolated antibody fragments, isolated monoclonal antibodies, isolated chimeric antibodies, and isolated humanized antibodies having the binding fragments of the B5 monoclonal antibody. Also disclosed are assays for detecting B. mallei, B. pseudomallei, or B. thailandensis in a sample, for detecting infection by B. mallei, B. pseudomallei, or B. thailandensis, and therapeutic methods for treating infections by B. mallei, B. pseudomallei, or B. thailandensis.

The present invention relates to a RNA encoding an antibody or a fragment or variant thereof and a composition, in particular a passive vaccine, comprising such an RNA. The present invention further relates to the use of such an RNA or of such a composition for treatment of tumours and cancer diseases, cardiovascular diseases, infectious diseases, autoimmune diseases, virus diseases and monogenetic diseases, e.g. also in gene therapy. The present invention also relates to a combination of at least two modified RNA's, in particular wherein one RNA encodes a heavy chain variable region of an antibody and another RNA encodes the corresponding light chain variable region of said antibody.

The invention relates to the field of biomedicine, and an anti-pertussis toxin (PT) single domain antibody and derivative protein thereof are disclosed. Specifically, a pertussis toxin-binding protein and use thereof are disclosed.

Disclosed herein are combinations of inhibitors of B cell maturation and recombinant nucleic acid molecules encoding synthethic antibodies, and their use for extending the duration of circulating synthetic antibodies and for treating diseases and disorders.